WallStreetZenWallStreetZen

NASDAQ: VNDA
Vanda Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VNDA

Based on 1 analyst offering 12 month price targets for Vanda Pharmaceuticals Inc

Min Forecast
$20.00+319.29%
Avg Forecast
$20.00+319.29%
Max Forecast
$20.00+319.29%

Should I buy or sell VNDA stock?

Based on 1 analyst offering ratings for Vanda Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VNDA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates VNDA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their VNDA stock forecasts and price targets.

VNDA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-18

1 of 1

Forecast return on equity

Is VNDA forecast to generate an efficient return?

Company
N/A
Industry
154.79%
Market
88.2%

Forecast return on assets

Is VNDA forecast to generate an efficient return on assets?

Company
N/A
Industry
32.71%

VNDA earnings per share forecast

What is VNDA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.12
Avg 2 year Forecast
-$0.27
Avg 3 year Forecast
$0.33

VNDA revenue forecast

What is VNDA's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$225.0M+13.2%
Avg 2 year Forecast
$308.9M+55.4%
Avg 3 year Forecast
$379.1M+90.72%
VNDA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VNDA revenue growth forecast

How is VNDA forecast to perform vs Biotechnology companies and vs the US market?

Company
24.44%
Industry
59.84%
Market
10.7%
VNDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VNDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VNDA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VNDA$4.77$20.00+319.29%Buy
PROK$0.94N/AN/A
CMPX$2.04$14.80+625.49%Strong Buy
OLMA$4.14$27.50+564.25%Buy
SEPN$6.14$34.00+453.75%Strong Buy
View Top Biotech Stocks

Vanda Pharmaceuticals Stock Forecast FAQ

Is Vanda Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: VNDA) stock is to Buy VNDA stock.

Out of 1 analyst, 0 (0%) are recommending VNDA as a Strong Buy, 1 (100%) are recommending VNDA as a Buy, 0 (0%) are recommending VNDA as a Hold, 0 (0%) are recommending VNDA as a Sell, and 0 (0%) are recommending VNDA as a Strong Sell.

If you're new to stock investing, here's how to buy Vanda Pharmaceuticals stock.

What is VNDA's earnings growth forecast for 2025-2027?

(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.81%.

Vanda Pharmaceuticals's earnings in 2025 is -$18,900,000.On average, 3 Wall Street analysts forecast VNDA's earnings for 2025 to be -$65,313,969, with the lowest VNDA earnings forecast at -$73,478,215, and the highest VNDA earnings forecast at -$54,233,921. On average, 2 Wall Street analysts forecast VNDA's earnings for 2026 to be -$15,453,752, with the lowest VNDA earnings forecast at -$43,737,033, and the highest VNDA earnings forecast at $12,829,530.

In 2027, VNDA is forecast to generate $19,244,295 in earnings, with the lowest earnings forecast at $19,244,295 and the highest earnings forecast at $19,244,295.

What is VNDA's revenue growth forecast for 2025-2027?

(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 24.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.84%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Vanda Pharmaceuticals's revenue in 2025 is $198,772,000.On average, 2 Wall Street analysts forecast VNDA's revenue for 2025 to be $13,121,109,900, with the lowest VNDA revenue forecast at $13,121,109,900, and the highest VNDA revenue forecast at $13,121,109,900. On average, 2 Wall Street analysts forecast VNDA's revenue for 2026 to be $18,013,825,992, with the lowest VNDA revenue forecast at $17,366,517,903, and the highest VNDA revenue forecast at $18,661,134,080.

In 2027, VNDA is forecast to generate $22,107,612,280 in revenue, with the lowest revenue forecast at $22,107,612,280 and the highest revenue forecast at $22,107,612,280.

What is VNDA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VNDA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.71%.

What is VNDA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year VNDA price target, the average VNDA price target is $20.00, with the highest VNDA stock price forecast at $20.00 and the lowest VNDA stock price forecast at $20.00.

The Wall Street analyst predicted that Vanda Pharmaceuticals's share price could reach $20.00 by Feb 18, 2026. The average Vanda Pharmaceuticals stock price prediction forecasts a potential upside of 319.29% from the current VNDA share price of $4.77.

What is VNDA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VNDA) Vanda Pharmaceuticals's current Earnings Per Share (EPS) is -$0.33. On average, analysts forecast that VNDA's EPS will be -$1.12 for 2025, with the lowest EPS forecast at -$1.26, and the highest EPS forecast at -$0.93. On average, analysts forecast that VNDA's EPS will be -$0.27 for 2026, with the lowest EPS forecast at -$0.75, and the highest EPS forecast at $0.22. In 2027, VNDA's EPS is forecast to hit $0.33 (min: $0.33, max: $0.33).

What is VNDA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VNDA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.